Published in Disease Risk Factor Week, February 28th, 2010
"Edaravone protected only against MPP+, and EGCG ((-)-epigallocatechin-3-O-gallate) protected only against 6-OHDA. Thus genomic responses to MPP+ and 6-OHDA in the presence of these antioxidants were analyzed using...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.